Bleeding with menopausal hormone therapy

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 23, Issue 1, 2009, Pages 141-149

  Hickey, Martha ^a   Agarwal, Sweta ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

hormone therapy; menopause; oestrogen; postmenopausal bleeding; progestogen; tibolone

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE RECEPTOR; SEX HORMONE; TIBOLONE;

AMENORRHEA; ANGIOGENESIS; CANCER RISK; CELL POPULATION; CLINICAL PROTOCOL; CONTRACEPTION; DRUG EFFICACY; ENDOMETRIUM CANCER; FEMALE; HEMOSTASIS; HORMONAL THERAPY; HUMAN; LEUKOCYTE; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MENOPAUSE; MENSTRUATION; OXYGENATION; PERFUSION; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VAGINA BLEEDING; VAGINAL DRYNESS;

AGED; ENDOMETRIUM; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; METRORRHAGIA; MIDDLE AGED; NORPREGNENES; POLYPS; POSTMENOPAUSE; UTERINE HEMORRHAGE;

EID: 58249089296     PISSN: 15216934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2008.07.001     Document Type: Review

References (73)

1. MacLennan A.H., Lester S., and Moore V. Oral estrogen replacement therapy versus placebo for hot flushes. Cochrane Database Syst Rev 288 (2002) CD002978
2. al-Azzawi F., and Habiba M. Regular bleeding on hormone replacement therapy: a myth?. Br J Obstet Gynaecol 101 (1994) 661-662
3. Limouzin-Lamothe M.A. What women want from hormone replacement therapy: results of an international survey. Eur J Obstet Gynecol Reprod Biol 64 (1996) S21-S24
4. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
5. Ettinger B., Li D.K., and Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Fertil Steril 69 (1998) 865-869
6. Elliott J., Connor M.E., and Lashen H. The value of outpatient hysteroscopy in diagnosing endometrial pathology in postmenopausal women with and without hormone replacement therapy. Acta Obstet Gynecol Scand 82 (2003) 1112-1119
7. Kloosterboer H. Intracrinology: the secret of the tissue-specificity of tibolone. J Br Menopause Soc 6 Suppl. (2000) 23-27
8. Bruce D., Robinson J., and Rymer J. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric 7 (2004) 261-266
9. Berning B., van Kuijk C., Bennink H.J., et al. Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas 35 (2000) 81-88
10. Christodoulakos G.E., Botsis D.S., Lambrinoudaki I.V., et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas 53 (2006) 413-423
11. Hammar M.L., van de Weijer P., Franke H.R., et al., TOTAL Study Investigators Group. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG 114 (2007) 1522-1529
12. Grady D., Gebretsadik T., Kerlikowske K., et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85 (1995) 304-313
13. Gambrell R. Strategies to reduce the incidence of endometrial cancer in postmenopausal women. Am J Obstet Gynecol 177 (1997) 1196-1204
14. de Lignieres B. Endometrial hyperplasia: risks, recognition and the search for a safe hormone replacement regimen. J Reprod Med 44 (1999) 191-196
15. Lethaby A., Farquhar C., Sarkis A., et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2 (2000) CD000402
16. Paganini-Hill R.R., and Henderson B.E. Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 59 (1989) 445-447
17. Wells M., Sturdee D.W., Barlow D.H., et al. Effect on endometrium of long term treatment with continuous combined estrogen/progestogen replacement therapy; follow up study. BMJ 325 (2002) 239-242
18. Charnock-Jones D.S., Macpherson A.M., Archer D.F., et al. The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum Reprod 15 Suppl. 3 (2000) 85-95
19. Wildemeersch D., Janssens D., Pylyser K., et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 57 (2007) 210-213
20. Bjarnason N.H. Endometrial cancer and hormone-replacement therapy. Lancet 366 (2005) 200-201
21. Pukkala E., Tulenheimo-Silfvast A., and Leminen A. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997. Cancer Causes Control 12 (2001) 111-115
22. Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy. Maturitas 57 (2007) 81-84
23. Hickey M., Higham J.M., and Fraser I.S. Hormone replacement therapy and irregular bleeding. Climacteric 4 (2001) 95-101
24. Hickey M., Pillai G., Higham J.M., et al. Changes in endometrial blood vessels in the endometrium of women with hormone replacement therapy-related irregular bleeding. Hum Reprod 18 (2003) 1100-1106
25. Hickey M., and Fraser I.S. Clinical implications of disturbances of uterine vascular morphology and function. Best Pract Res Clin Obstet Gynaecol 14 (2000) 937-951
26. Hickey M., and Fraser I. Human uterine vascular structures in normal and diseased states. Microsc Res Tech 60 (2003) 377-389
27. Johannisson E., Holinka C.F., and Arrenbrecht S. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium. Int J Fertil Womens Med 42 Suppl. 2 (1997) 388-398
28. Markee J.E. Menstruation in intraocular endometrial transplants in the Rhesus monkey. Am J Obstet Gynecol 131 (1978) 558-559
29. Hickey M., Dwarte D., and Fraser I.S. Superficial endometrial vascular fragility in Norplant users and in women with ovulatory dysfunctional uterine bleeding. Hum Reprod 15 (2000) 1509-1514
30. Hickey M., and d'Arcangues C. Mechanisms underlying menstrual bleeding disturbances with progestogens. Ernst Schering Res Found Workshop 52 (2005) 191-217
31. Hickey M., Doherty D.A., Fraser I.S., et al. Why does menopausal hormone therapy (HT) lead to irregular uterine bleeding? Changes to endometrial blood vessels. Hum Reprod 23 4 (2008 Apr) 912-918 Epub 2008 Jan 23.
32. Rogers P.A., Plunkett D., and Affandi B. Perivascular smooth muscle alpha-actin is reduced in the endometrium of women with progestin-only contraceptive breakthrough bleeding. Hum Reprod 15 Suppl. 3 (2000) 78-84
33. Hickey M., Simbar M., Markham R., et al. Changes in vascular basement membrane in the endometrium of Norplant users. Hum Reprod 14 (1999) 716-721
34. Runic R., Schatz F., Wan L., et al. Effects of Norplant on endometrial tissue factor expression and blood vessel structure. J Clin Endocrinol Metab 85 (2000) 3853-3859
35. Jabbour H.N., Kelly R.W., Fraser H.M., et al. Endocrine regulation of menstruation. Endocr Rev 27 (2006) 17-46
36. Milling Smith O., and Critchley H.O.D. Progestogen only contraception and endometrial break through bleeding. Angiogenesis 8 (2005) 117-126
37. Chauchereau A., Savouret J.F., and Milgrom E. Control of biosynthesis and post-transcriptional modification of the progesterone receptor. Biol Reprod 46 (1992) 174-177
38. Perrot-Applanat M., Groyer-Picard M.T., Garcia E., et al. Immunocytochemical demonstration of estrogen and progesterone receptors in muscle cells of uterine arteries in rabbits and humans. Endocrinology 123 (1988) 1511-1519
39. Critchley H.O., Brenner R.M., Henderson T.A., et al. Estrogen receptor beta, but not estrogen receptor alpha, is present in the vascular endothelium of the human and nonhuman primate endometrium. J Clin Endocrinol Metab 86 (2001) 1370-1378
40. Bamberger A.M., Milde-Langosch K., Loning T., et al. The glucocorticoid receptor is specifically expressed in the stromal compartment of the human endometrium. J Clin Endocrinol Metab 86 (2001) 5071-5074
41. Mertens H.J., Heineman M.J., Theunissen P.H., et al. Androgen, estrogen and progesterone receptor expression in the human uterus during the menstrual cycle. Eur J Obstet Gynecol Reprod Biol 98 (2001) 58-65
42. Vani S., Critchley H.O., Fraser I.S., et al. Endometrial expression of steroid receptors in postmenopausal hormone replacement therapy users: relationship to bleeding patterns. J Fam Plann Reprod Health Care 34 (2008) 27-34
43. Krikun G., Schatz F., Taylor R., et al. Endometrial endothelial cell steroid receptor expression and steroid effects on gene expression. J Clin Endocrinol Metab 90 (2005) 1812-1818
44. Dahmoun M., Odmark I.S., Risberg B., et al. Apoptosis, proliferation, and sex steroid receptors in postmenopausal endometrium before and during HRT. Maturitas 49 (2004) 114-123
45. Salamonsen L.A., and Lathbury L.J. Endometrial leukocytes and menstruation. Hum Reprod Update 6 (2000) 16-27
46. Birkedal-Hansen H., Moore W.G., Bodden M.K., et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4 (1993) 197-250
47. Vassilev V., Pretto C.M., Cornet P.B., et al. Response of matrix metalloproteinases and tissue inhibitors of metalloproteinases messenger ribonucleic acids to ovarian steroids in human endometrial explants mimics their gene- and phase-specific differential control in vivo. J Clin Endocrinol Metab 90 (2005) 5848-5857
48. Zhang J., Hampton A.L., Nie G., et al. Progesterone inhibits activation of latent matrix metalloproteinase (MMP)-2 by membrane-type 1 MMP: enzymes coordinately expressed in human endometrium. Biol Reprod 62 (2000) 85-94
49. Zhang J., and Salamonsen L.A. In vivo evidence for active matrix metalloproteinases in human endometrium supports their role in tissue breakdown at menstruation. J Clin Endocrinol Metab 87 (2002) 2346-2351
50. Skinner J.L., Riley S.C., Gebbie A.E., et al. Regulation of matrix metalloproteinase-9 in endometrium during the menstrual cycle and following administration of intrauterine levonorgestrel. Hum Reprod 14 (1999) 793-799
51. Marbaix E., Vekemans M., Galant C., et al. Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant users. Hum Reprod 15 Suppl. 3 (2000) 120-134
52. Vincent A.J., Zhang J., Ostor A., et al. Decreased tissue inhibitor of metalloproteinase in the endometrium of women using depot medroxyprogesterone acetate: a role for altered endometrial matrix metalloproteinase/tissue inhibitor of metalloproteinase balance in the pathogenesis of abnormal uterine bleeding?. Hum Reprod 17 (2002) 1189-1198
53. Song J.Y., Russell P., Markham R., et al. Effects of high dose progestogens on white cells and necrosis in human endometrium. Hum Reprod 11 (1996) 1713-1718
54. Vincent A.J., and Salamonsen L.A. The role of matrix metalloproteinases and leukocytes in abnormal uterine bleeding associated with progestin-only contraceptives. Hum Reprod 15 Suppl. 3 (2000) 135-143
55. Hickey M., Higham J., Sullivan M., et al. Endometrial bleeding in hormone replacement therapy users: preliminary findings regarding the role of matrix metalloproteinase 9 (MMP-9) and tissue inhibitors of MMPs. Fertil Steril 75 (2001) 288-296
56. Hickey M., Crewe J., Mahoney L.A., et al. Mechanisms of irregular bleeding with hormone therapy: the role of matrix metalloproteinases and their tissue inhibitors. J Clin Endocrinol Metab 91 8 (2006 Aug) 3189-3198 Epub 2006 May 9.
57. Murphy A.N., Unsworth E.J., and Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157 (1993) 351-358
58. Critchley H.O., Kelly R.W., Baird D.T., et al. Regulation of human endometrial function: mechanisms relevant to uterine bleeding. Reprod Biol Endocrinol 4 Suppl. 1 (2006) S5
59. Hickey M., Crewe J., Goodridge J., et al. Menopausal hormone therapy and irregular endometrial bleeding: a potential role for uterine natural killer cells?. J Clin Endocrinol Metab 90 (2005) 5528-5535
60. Popovici R.M., Irwin J.C., Giaccia A.J., et al. Hypoxia and cAMP stimulate vascular endothelial growth factor (VEGF) in human endometrial stromal cells: potential relevance to menstruation and endometrial regeneration. J Clin Endocrinol Metab 84 (1999) 2245-2248
61. Sharkey A.M., Day K., McPherson A., et al. Vascular endothelial growth factor expression in human endometrium is regulated by hypoxia. J Clin Endocrinol Metab 85 (2000) 402-409
62. Krikun G., Schatz F., Finlay T., et al. Expression of angiopoietin-2 by human endometrial endothelial cells: regulation by hypoxia and inflammation. Biochem Biophys Res Commun 275 (2000) 159-163
63. Maisonpierre P.C., Suri C., Jones P.F., et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277 (1997) 55-60
64. Bulger E.M., and Maier R.V. Antioxidants in critical illness. Arch Surg 136 (2001) 1201-1207
65. Hickey M., Dwarte D., and Fraser I.S. Precise measurements of intrauterine vascular structures at hysteroscopy in menorrhagia and during Norplant use. Hum Reprod 13 (1998) 3190-3196
66. Hickey M., Carati C., Manconi F., et al. The measurement of endometrial perfusion in norplant users: a pilot study. Hum Reprod 15 (2000) 1086-1091
67. Hickey M, Krikun G, Carati C, et al. LTPOC results in endometrial vasomotor instability, hypoxia/reperfusion and bleeding, vol. 212A, 394. Los Angeles; 2005.
68. Akkad A.A., Habiba M.A., Ismail N., et al. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol 86 (1995) 330-334
69. Van den Bosch T., Van Schoubroeck D., Ameye L., et al. Ultrasound assessment of endometrial thickness and endometrial polyps in women on hormonal replacement therapy. Am J Obstet Gynecol 188 (2003) 1249-1253
70. Archer D.F. Endometrial bleeding during hormone therapy: the effect of progestogens. Maturitas 57 (2007) 71-76
71. Archer D.F., Dorin M., Lewis V., et al. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 75 (2001) 1080-1087
72. Thomas A.M., Hickey M., and Fraser I.S. Disturbances of endometrial bleeding with hormone replacement therapy. Hum Reprod 15 (2000) 7-17
73. Langer R.D., Pierce J.J., O'Hanlan K.A., et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal estrogen/progestin interventions. Trial N Engl J Med 337 25 (1997 Dec 18) 1792-1798